

## Age and Incidence of Pharyngeal Candidiasis in Patients Undergoing Bronchoscopy

Tauseef Neem Rashid Akhtar<sup>1</sup>, Pankaj Bhat<sup>2</sup>, Yatin Wagh<sup>3</sup>

<sup>1</sup>Assistant Professor, Respiratory Medicine, JMF's, A.C.P.M. Medical College & Hospital, Sakri Road, Dhule, M.S.

<sup>2</sup>Assistant Professor, Otorhinolaryngology, JMF's, A.C.P.M. Medical College & Hospital, Sakri Road, Dhule, M.S.

<sup>3</sup>Assistant Professor, General Surgery, JMF's, A.C.P.M. Medical College & Hospital, Sakri Road, Dhule, M.S.

Received: 18-06-2023 / Revised: 21-07-2023 / Accepted: 26-08-2023

Corresponding author: Dr. Tauseef Neem Rashid Akhtar

Conflict of interest: Nil

### Abstract:

Candidiasis is a type of fungal infection that often spreads to the skin, mouth, throat, oesophagus, and vagina. It is caused by the build-up of yeast called *Candida*. Multiple types of *Candida* can be infective agents, with *C. albicans* being the most prevalent. When it spreads to the mouth and throat, it is called thrush otherwise known as Oropharyngeal Candidiasis. In this retrospective study, the frequency of candidiasis in the "throat" (pharyngeal), was examined exclusively in 1255 patients who underwent bronchoscopy. Most of the findings of pharyngeal candidiasis were incidental.

The objective of this retrospective study was to investigate whether or not age was a factor in the occurrence of pharyngeal candidiasis in patients undergoing bronchoscopy. The age of the sample ranged from 18-95 years. It was found that the lowest incidence of pharyngeal candidiasis was at age  $\leq 25$  (0.2%). Moreover, at ages 26 to 50 years there was a moderate chance of having the condition (9.3%). As well between ages 76-100 years, there was slightly more incidence (16.1%). The highest incidence of presenting pharyngeal candidiasis was between ages 51-75 years (39.2%). Furthermore, additional study is required before confirming a link between age and pharyngeal candidiasis.

**Keywords:** Bronchoscopy- pharyngeal candidiasis- anti-fungal drug-immunosuppressant- comorbidity- diabetic patients.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

### Introduction

Candidiasis, otherwise known as moniliasis is a fungal infection caused by yeasts that belong to the genus *Candida*. The most prevalent of the *Candida* family is *C. albicans* (*Monilia albicans*). Some lesser-known types include *C. glabrata*, *C. Krusei*, and *C. tropicalis* [2]. These yeasts normally reside in the gastrointestinal tract and may appear on mucous membranes without inducing an infection [3]. As well they are regulated by the body's own native bacteria and immune defences often occur in pregnant or diabetic women [1].

As a result, patients may present with white or yellow vaginal discharge (leukorrhoea), burning and itching of genitalia [7,8]. Cutaneous Candidiasis causes patches of red, moist and sensitive skin [2]. The most severe is systemic candidiasis (invasive). This is when *Candida* spreads to the bloodstream (candidemia) and may lead to potentially fatal conditions like septic shock [9]. Furthermore, pharyngeal candidiasis is usually diagnosed by

physical examination and culture samples [2]. It may be treated by using topical antifungal Agents such as clotrimazole and nystatin for a few weeks [1,3]. This is similar to the treatments for cutaneous and vaginal candidiasis. Treatment for systemic candidiasis is typically indicated in immunocompromised patients. The usual treatment is the use of an intravenous anti-fungal drug such as fluconazole or caspofungin [1,3,10].

### Methodology:

The method involved reviewing patient files from 2021-2013. The statistical software used for data analysis was IBM SPSS Statistics v25. The level of significance used based on rejecting or retaining the null hypotheses ( $H_0$ ) was 0.05. The null hypothesis was that there "Is no difference between age and the incidence of pharyngeal candidiasis". If the p-value achieved in the study was less than 0.05,  $H_0$  would be rejected. In contrast if  $H_0$  was greater than 0.05,  $H_0$  would be retained. A 95%

confidence interval was deployed. As well, statistical methods used for analysis included an independent sample t-test, binary logistic regression, histogram, boxplot and a frequency table.

## Results

There were 1255 patients who participated in the study. In Table 1, it was seen there were 5 patients aged  $\leq 25$  years. Ages 26-50 had about 157 (12.4%) patients. Ages 51-75 had 736 (58.6%) patients. Finally, the oldest group had about 357 patients. Furthermore, out of those presenting

pharyngeal candidiasis, 3 (0.2%) were patients aged  $\leq 25$  years. About 117 (9.3%) patients aged 26-50 had pharyngeal candidiasis, whereas 203 (16.1%) patients between ages 76- 100 had pharyngeal candidiasis. Age group 51-75 had the highest number of patients presenting pharyngeal candidiasis at 494 (39.2%). The data displayed a small lack of uniformity. The distribution also appears to be slightly skewed to the left. The average mean of those with pharyngeal candidiasis was 65.4 years with a standard deviation of about 13.0.

**Table 1: T-test of patient age and incidence of candidiasis**

		Sample (N)	Mean Age (years) SD	Difference in means	P-Value	95% CL
Candidiasis	Yes	817	65.39 (12.99)	-3.397	< 0.0001	[-4.915, -1.879]
	No	438	68.79 (13.10)			

\*P-Value Reported from Independent Sample t-test; CI: Confidence Interval.

**Table 2: Patient comorbidity**

Patient Comorbidity	Diabetes Mellitus	Immunosuppressed (Long term Immunosuppressants)
<b>Patient subset:</b>		
Ages $\leq 25$	0	0
Ages 26-50	0	11 (0.88%)
Ages 51-75	110 (8.8%)	29 (2.3%)
Ages 76-100	49 (3.9%)	17 (1.4%)
<b>Total</b>	159 (12.6%)	57 (4.5%)
<b>Presenting pharyngeal candidiasis:</b>		
Ages $\leq 25$	0	0
Ages 26-50	0	8 (0.6%)
Ages 51-75	91 (7.3%)	21 (1.67%)
Ages 76-100	37 (2.9%)	11 (0.88%)
<b>Total</b>	128 (10.2%)	112 (8.9%)

Immunosuppressed category refers to patients on long term immune suppressants (ex. steroids). Subset of patients from Table 1, values recorded as frequency and valid percent.

An independent sample t-test was conducted (Table 1), and it was seen that the mean age for those with pharyngeal candidiasis was 65.39 years, with a standard deviation of 12.99 years. Whereas for those that without the condition was 68.79 years, with a standard deviation of 13.10 years. The difference in means between those with and without candidiasis was -3.397 years. The p-value was lower than the set level of 0.05, being less than 0.0001. As well the confidence interval had a lower limit of [-4.915] and an upper limit of [-1.879].

A logistic regression analysis was carried out to predict pharyngeal candidiasis using the different age groups. Ages 76-100, was used a reference point for comparing with other ages. It was also seen that there was an odds ratio of 1.138 for those  $\leq 25$ . A slightly higher odds ratio of 1.549 was seen for age group 51-75. The highest ratio was seen between in age group 26-50 at 2.219. Both age

groups 51-75 and 26-50 had significant P-values, of 0.000 and 0.001 respectively.

## Discussion

When examining the patient characteristics, it was seen that most of the patients in the study displayed pharyngeal candidiasis. Those in age group 51-75 had the highest incidence of candidiasis (39.2%), whereas those  $\leq 25$  had the least incidence (0.2%). As well a majority of the patients in the study were between 51-75 years of age. The least amount of participants were found in the youngest age groups less than/equal to 25 years. When examining patient comorbidity (Table 2), diabetic patients aged 51-75 had the most pharyngeal candidiasis (7.3%) out of all the age groups. Diabetic age group 76-100 had 37 (2.9%) patients with pharyngeal candidiasis. In contrast to the other age groups, there were no diabetic patients in age groups  $\leq 25$  and 26-50. There were the most immunosuppressed patients (those on long term immunosuppressants), in the age group 51-75 who presented with pharyngeal candidiasis (1.67%). Furthermore, there were no immunosuppressed patients  $\leq 25$ . Out of the age groups that did have

immunosuppressed patients, age group 26-50 had the least number of patients with pharyngeal candidiasis (0.6%). The independent sample T-test had a p-value of  $< 0.0001$  and was statistically significant, suggesting there was in fact a difference between age and the incidence of pharyngeal candidiasis (Table 1). Thus, the null hypothesis that there is no difference between age and the incidence of pharyngeal candidiasis was rejected. The mean age of those with Candidiasis was 65.39 (12.99) years, which showed some discrepancies, to those who did not present the condition with a mean age of 68.79 (13.10) years. The difference in means was 3.397 years lower for those with candidiasis and had an interval between -4.195 and -1.879. This means that those with candidiasis tend to be 3.4 years younger than those without the condition. The binary logistic regression showed that those who were in ages groups 26-50 were more than 2.219 times more likely to have candidiasis compared to those between 76-100. Furthermore, those that are between ages 51-75 and  $\leq 25$ , were also slightly more likely at 1.549 and 1.138 respectively, to have the condition compared to ages 76-100.

#### Limitations

Some limitations in the study include the population size. Ideally it would be beneficial to have a larger sample size to increase accuracy and reduce the possibility of errors. Furthermore, a majority of the patients, were somewhere in the range of 60 to 80 years of age. This could have heavily influenced the data.

#### Conclusion

Being aware of the potential risk factors for pharyngeal candidiasis is not only important knowledge for a physician, but for the health of their patient. Pharyngeal candidiasis may lead to burning or painful sensations, bleeding, loss of taste and impediment of eating or swallowing. It may also lead to fungal pneumonia and rarely systemic fungal infection [1]. Being able to identify an association between possible factors and causes would be of great benefit to the patient.

Once again, the aim of the study was to investigate whether or not age was a factor in the occurrence of pharyngeal candidiasis in patients undergoing bronchoscopy. It was seen that there was a statistically significant difference in age and the incidence of candidiasis. This was suggested through the p-value  $< 0.0001$ , being less than 0.05 upon statistical analysis (independent sample T-test) and the null hypothesis being rejected. As well those with pharyngeal candidiasis tended to be about 3.4 years younger than those without the

condition. The lowest incidence of pharyngeal candidiasis once again was at age's  $\leq 25$  (0.2%). Moreover, at ages 26 to 50 years there was a moderate chance of having the condition (9.3%). As well between ages 76-100 years, there was slightly more incidence (16.1%). The highest incidence of presenting pharyngeal candidiasis was between ages 51-75 years (39.2%). Considering only patient comorbidity, diabetic patients aged 51-75 had the most pharyngeal candidiasis (7.3%) out of all the age groups. As well, in immunosuppressed patients, age group 51-75 presented with the most pharyngeal candidiasis (1.67%). Despite these findings, all other age groups have a higher likelihood for pharyngeal candidiasis compared to those between ages 76-100 years (binary logistic regression). Furthermore, supplementary studies will be required for more conclusive results.

#### References

1. Epstein JB, Polsky B. Oropharyngeal candidiasis: A review of its clinical spectrum and current therapies. *Clin Ther.* 1998; 20: 40-57.
2. Singh A, Verma R, Murari A, Agrawal A. Oral candidiasis: An overview. *J Oral Maxillofac Pathol.* 2014; 18: 81-85.
3. Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: Traditional and alternative antifungal agents. *Biomed Res Int.* 2013.
4. Scully C, El-Kabir M, Samaranayake LP. Candida and oral candidiasis: A review. *Critical Reviews in Oral Biology & Medicine* 1994;5: 125-157.
5. Patil S, Rao RS, Majumdar B, Anil S. Clinical appearance of oral candida infection and therapeutic strategies. *Front Microbiol.* 2015; 6: 1391.
6. Akpan A, Morgan R. Oral candidiasis. *Postgraduate Medical Journal.* 2002; 78: 455-459.
7. Bodey GP, Anaissie EJ. chronic systemic candidiasis. *Eur J Clin Microbiol Infect Dis.* 1989; 8: 855-857.
8. Nyirjesy P. Chronic vulvovaginal candidiasis. *Am Fam Physician.* 2001; 63: 697-702.
9. Vena A, Bouza E, Valerio M, Padilla B, Paño-Pardoet JP, al. Candidemia in non-ICU surgical wards: Comparison with medical wards. *PLoS One.* 2017; 12: e0185339.
10. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, et al. Practice guidelines for the treatment of candidiasis. *Clinical Infectious Diseases.* 2000; 30: 662-678.